申请人:Sankyo Company, Limited
公开号:US05635534A1
公开(公告)日:1997-06-03
Compounds of formula (I): ##STR1## (wherein: R.sup.0 is hydrogen, methyl or hydroxymethyl; R.sup.1 is substituted alkyl; R.sup.2 and R.sup.3 are each hydrogen, halogen, hydroxy, alkoxy, carboxy, alkoxycarbonyl, alkyl, nitro, haloalkyl, or substituted alkyl; X is oxygen or sulfur; and Ar optionally substituted phenyl or naphthyl); and pharmaceutically acceptable salts thereof have a variety of valuable pharmaceutical activities, including anti-diabetic and anti-obesity activities; in addition, they are capable of treating or preventing hyperlipemia and hyperglycemia and, by inhibiting the action of aldose reductase, they can also be effective in the treatment and prevention of complications of diabetes.
式(I)的化合物:##STR1##(其中:R.sup.0为氢、甲基或羟甲基;R.sup.1为取代的烷基;R.sup.2和R.sup.3分别为氢、卤素、羟基、烷氧基、羧基、烷氧羰基、烷基、硝基、卤代烷基或取代的烷基;X为氧或硫;Ar为可选取代的苯基或萘基);以及其药学上可接受的盐具有各种有价值的药理活性,包括抗糖尿病和抗肥胖活性;此外,它们能够治疗或预防高脂血症和高血糖症,并通过抑制醛固酮还原酶的作用,也可以在糖尿病并发症的治疗和预防中发挥作用。